96 related articles for article (PubMed ID: 9748126)
1. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
2. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
[TBL] [Abstract][Full Text] [Related]
3. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model.
Cui Z; Qiu F
Cancer Immunol Immunother; 2006 Oct; 55(10):1267-79. PubMed ID: 16362407
[TBL] [Abstract][Full Text] [Related]
4. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.
Mine T; Gouhara R; Hida N; Imai N; Azuma K; Rikimaru T; Katagiri K; Nishikori M; Sukehiro A; Nakagawa M; Yamada A; Aizawa H; Shirouzu K; Itoh K; Yamana H
Cancer Sci; 2003 Jun; 94(6):548-56. PubMed ID: 12824881
[TBL] [Abstract][Full Text] [Related]
5. Immunological evaluation of personalized peptide vaccination for patients with histologically unfavorable carcinoma of unknown primary site.
Sakamoto S; Yutani S; Shichijo S; Morita M; Yamada A; Itoh K; Noguchi M
Cancer Immunol Immunother; 2016 Oct; 65(10):1223-31. PubMed ID: 27549314
[TBL] [Abstract][Full Text] [Related]
6. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer.
Cui Z; Huang L
Cancer Immunol Immunother; 2005 Dec; 54(12):1180-90. PubMed ID: 15846491
[TBL] [Abstract][Full Text] [Related]
7. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
[TBL] [Abstract][Full Text] [Related]
8. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.
Sato Y; Shomura H; Maeda Y; Mine T; Une Y; Akasaka Y; Kondo M; Takahashi S; Shinohara T; Katagiri K; Sato M; Okada S; Matsui K; Yamada A; Yamana H; Itoh K; Todo S
Cancer Sci; 2003 Sep; 94(9):802-8. PubMed ID: 12967479
[TBL] [Abstract][Full Text] [Related]
9. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
[TBL] [Abstract][Full Text] [Related]
10. HLA typing demands for peptide-based anti-cancer vaccine.
Nagorsen D; Thiel E
Cancer Immunol Immunother; 2008 Dec; 57(12):1903-10. PubMed ID: 18317754
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
Takeuchi S; Kagabu M; Shoji T; Nitta Y; Sugiyama T; Sato J; Nakamura Y
Oncoimmunology; 2020 Nov; 9(1):1838189. PubMed ID: 33235818
[TBL] [Abstract][Full Text] [Related]
12. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer.
Furukawa Y; Ishii M; Ando J; Ikeda K; Igarashi KJ; Kinoshita S; Azusawa Y; Toyota T; Honda T; Nakanishi M; Ohshima K; Masuda A; Yoshida E; Kitade M; Porteus M; Terao Y; Nakauchi H; Ando M
Cell Rep Med; 2023 Dec; 4(12):101327. PubMed ID: 38091985
[TBL] [Abstract][Full Text] [Related]
13. Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma.
Tsukahara T; Watanabe K; Murata K; Takahashi A; Mizushima E; Shibayama Y; Kameshima H; Hatae R; Ohno Y; Kawahara R; Murai A; Nakatsugawa M; Kubo T; Kanaseki T; Hirohashi Y; Terui T; Asanuma H; Hasegawa T; Sato N; Torigoe T
Cancer Immunol Immunother; 2020 Feb; 69(2):189-197. PubMed ID: 31853575
[TBL] [Abstract][Full Text] [Related]
14. Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Ciardiello D; Maglione A; Orditura M; Lorusso D; Maiello E
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497437
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.
Schmidt MW; Battista MJ; Schmidt M; Garcia M; Siepmann T; Hasenburg A; Anic K
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053603
[TBL] [Abstract][Full Text] [Related]
16. Vaccination Against Cervical Cancer: Hopes and Realities.
Da Silva DM; Kast WM
Am J Cancer (Auckl); 2005 Jul; 4(4):207-219. PubMed ID: 34566405
[TBL] [Abstract][Full Text] [Related]
17. Palmitoylated antigens for the induction of anti-tumor CD8
Stolk DA; Horrevorts SK; Schetters STT; Kruijssen LJW; Duinkerken S; Keuning E; Ambrosini M; Kalay H; van de Ven R; Garcia-Vallejo JJ; de Gruijl TD; van Vliet SJ; van Kooyk Y
Mol Ther Oncolytics; 2021 Jun; 21():315-328. PubMed ID: 34141869
[TBL] [Abstract][Full Text] [Related]
18. Regulatory T Cells in Gynecologic Cancer.
Ou Y; Cannon MJ; Nakagawa M
MOJ Immunol; 2018; 6(2):34-42. PubMed ID: 30637330
[TBL] [Abstract][Full Text] [Related]
19. The dawn of vaccines for cancer prevention.
Finn OJ
Nat Rev Immunol; 2018 Mar; 18(3):183-194. PubMed ID: 29279613
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7.
Tsang KY; Fantini M; Fernando RI; Palena C; David JM; Hodge JW; Gabitzsch ES; Jones FR; Schlom J
Vaccine; 2017 May; 35(19):2605-2611. PubMed ID: 28389098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
